Mechanistically, our data reveal that knockdown of KRAS inhibits matrix metalloproteinase (MMP1), MMP3, and MMP9, which are known as tumor metastasis-related proteins, via an IL-17 signal-dependent manner. The gene discussed is IL17A; the disease is neoplasm.